CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares saw an uptick in trading volume on Tuesday . 248,997 shares changed hands during mid-day trading, an increase of 54% from the previous session’s volume of 162,202 shares.The stock last traded at $2.24 and had previously closed at $2.21.

A number of research firms have recently weighed in on CBAY. Roth Capital began coverage on shares of CymaBay Therapeutics in a research note on Friday, July 1st. They issued a “buy” rating on the stock. Zacks Investment Research raised shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, June 27th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of CymaBay Therapeutics in a research note on Thursday, May 12th.

The company has a 50-day moving average of $1.79 and a 200-day moving average of $1.75. The firm’s market cap is $53.69 million.

CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. On average, analysts anticipate that CymaBay Therapeutics Inc. will post ($1.21) EPS for the current fiscal year.

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.